(E)-3-(3-hydroxy-4-methoxybenzylidene)-1-methylindolin-2-one | 1148119-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (E)-3-(3-hydroxy-4-methoxybenzylidene)-1-methylindolin-2-one
• 英文别名: (3E)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-1-methylindol-2-one
• CAS: 1148119-20-3
• 化学式: C₁₇H₁₅NO₃
• 分子量: 281.311
• InChiKey: WNROXVDYBCVQOT-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异香兰素 、 N-甲基吲哚酮 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 0.25h， 以39%的产率得到(E)-3-(3-hydroxy-4-methoxybenzylidene)-1-methylindolin-2-one
  参考文献：
  名称：

  Functionalized 3-benzylidene-indolin-2-ones: Inducers of NAD(P)H-quinone oxidoreductase 1 (NQO1) with antiproliferative activity

  摘要：

  Functionalized benzylidene-indolin-2-ones are widely associated with antiproliferative activity. The scaffold is not normally associated with chemoprevention in spite of the presence of a nitrogen-linked Michael acceptor moiety that may predispose members to induction of NQO1, a widely used biomarker of chemopreventive potential. To investigate this possibility, we have synthesized and evaluated a series of functionalized 3-benzylidene-indolin-2-ones for induction of NQO1 in murine Hepa1c1c7 cells as well as antiproliferative activity against two human cancer cell lines (MCF-7, HCT116). The benzylideneindolinones were found to be good inducers of NQO1 activity, with 85% of test compounds able to increase basal NQO1 activity by more than twofold at concentrations of <= 10 mu M. By contrast, fewer compounds (11%) tested at the same concentration were able to reduce cell viability by more than 50%. Structure activity relationships showed that the nitrogen linked Michael acceptor moiety was an essential requirement for both activities. This common feature notwithstanding, substitution of the 3-benzylidene-indolin-2-one core structure affected NQO1 induction and antiproliferative activities in dissimilar ways, underscoring different structural requirements for these two activities. Nonetheless, promising compounds ( 10, 42, 45-48) were identified that combine selective induction of NQO1 with potent antiproliferative activity. A potential advantage of such agents would be the ability to provide added protection to normal cells by the up-regulation of NQO1 and other phase II enzymes while simultaneously targeting neoplastic cells. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.052

文献信息

• Novel therapeutic target for protozoal diseases
  申请人：Rathore Dharmender

  公开号：US20070148185A1

  公开（公告）日：2007-06-28

  A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on HDP, or antigenic epitopes of HDP, either alone or in combination with other parasite antigens. Methods for the development and use of compounds that inhibit the catalytic activity of HDP, and diagnostic and laboratory methods utilizing HDP are also provided. HDP is also referred to herein as Fasciclin Related Adhesive Protein (FRAP).
• [EN] A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES<br/>[FR] UNE NOUVELLE CIBLE THÉRAPEUTIQUE POUR LES MALADIES À PROTOZOAIRE
  申请人：VIRGINIA TECH INTELL PROP

  公开号：WO2007047579A2

  公开（公告）日：2007-04-26

  [EN] A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on HDP, or antigenic epitopes of HDP, either alone or in combination with other parasite antigens. Methods for the development and use of compounds that inhibit .the catalytic activity of HDP, and diagnostic and laboratory methods utilizing HDP are also provided. HDP is also referred to herein as Fasciclin Related Adhesive Protein (FRAP).
  [FR] L'invention concerne une nouvelle protéine de désintoxication de l'hémozoïne (PDH) de plasmodium et de parasites apparentés, comme cible pour intervention thérapeutique dans des maladies causées par lesdits parasites. La PDH s'est avéré jouer un rôle critique dans l'adhésion à des, ou l'invasion de, cellules hôtes par le parasite. En outre, La PDH catalyse la neutralisation de l'hème par le parasite, en encourageant sa polymérisation en hémozoïne. La présente invention concerne des méthodes et des compositions pour des thérapies basées sur l'administration de vaccins à base de protéine, d'ADN ou de cellules, et/ou d'anticorps basés sur la PDH ou d'épitopes antigènes de la PDH, seuls ou en combinaison avec d'autres antigènes de parasites. L'invention concerne aussi des méthodes pour développer et utiliser des composés qui inhibent l'activité catalytique de la PDH, et des méthodes diagnostiques et de laboratoire utilisant la PDH. On fait également référence ici à la PDH comme protéine adhésive apparentée à la fascicline (FRAP : Fasciclin Related Adhesive Protein).